Toxicological Evaluation of Kaempferol and Linearolactone as Treatments for Amoebic Liver Abscess Development in Mesocricetus auratus
- PMID: 39408962
- PMCID: PMC11477209
- DOI: 10.3390/ijms251910633
Toxicological Evaluation of Kaempferol and Linearolactone as Treatments for Amoebic Liver Abscess Development in Mesocricetus auratus
Abstract
Several studies with kaempferol (KP) and linearolactone (LL) have demonstrated their antiparasitic activity. However, the toxicity of these treatments is unknown. Therefore, this study aimed to evaluate the possible toxicological effects of intraperitoneal (i.p.) administration of KP or LL on the amoebic liver abscess model (ALA) in Mesocricetus auratus. An ALA was induced in male hamsters with 1.5 × 105Entamoeba histolytica (E. histolytica) trophozoites inoculated in the left hepatic lobe. The lesion evolved for 4 days, and then KP (5 mg/kg body weight/day) or LL (10 mg/kg body weight/day) was administered for 4 consecutive days. Then, magnetic resonance imaging (MRI), paraclinical analyses, and necropsy for histopathological evaluation were performed. There was similar ALA inhibition by KP (19.42%), LL (28.16%), and metronidazole, the antiamoebic control (20.87%) (p ≤ 0.05, analysis of variance [ANOVA]). There were hepatic and renal biochemical alterations in all treatment groups, mainly for KP (aspartate aminotransferase: 347.5 ± 37.5 U/L; blood urea nitrogen: 19.4 ± 1.9 g/dL; p ≤ 0.05, ANOVA). Lesions found in the organs were directly linked to the pathology. In conclusion, KP and LL decreased ALA development and exerted fewer toxicological effects compared with metronidazole. Therefore, both compounds exhibit therapeutic potential as an alternative treatment of amoebiasis caused by E. histolytica. However, additional clinical studies in different contexts are required to reaffirm this assertion.
Keywords: Entamoeba histolytica; Mesocricetus auratus; amoebic liver abscess; kaempferol; linearolactone; toxicity.
Conflict of interest statement
The authors declare that they have no conflicts of interest. The funders had no role in this study design, in the collection, analysis, or interpretation of data, in writing the manuscript, or in the decision to publish the results.
Figures
References
-
- WHO Diarrheal Disease. 2017. [(accessed on 23 December 2023)]. Available online: https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease.
-
- Shirley D.A., Hung C.C., Moonah S. Part 5, Protozoal Infections: Chapter 94—Entamoeba histolytica (Amebiasis) In: Ryan E.T., Hill D.R., Solomon T., Aronson N.E., Endy T.P., editors. Hunter’s Tropical Medicine and Emerging Infectious Diseases. 10th ed. Elsevier; Toronto, ON, Canada: 2020. pp. 699–706. - DOI
-
- Gómez-García C., Marchat L.A., López-Cánovas L., Pérez-Ishiwara D.G., Rodríguez M.A., Orozco E. Part—Parasitic Drug Resistance, Mechanisms: Chapter—Drug Resistance Mechanisms in Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, and Opportunistic Anaerobic Protozoa. In: Mayers D.L., Sobel J.D., Oullette M., Kaye K.S., Marchaim D., editors. Antimicrobial Drug Resistance. Mechanisms of Drug Resistance. 1st ed. Springer; Cham, Switzerland: 2017. pp. 613–628. - DOI
-
- VADEMECUM Metronidazole. 2017. [(accessed on 23 December 2023)]. Available online: https://www.vademecum.es/principios-activos-metronidazol-J01XD01.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
